3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Multiple Myeloma
9
Lymphoma, Non-Hodgkin
7
Carcinoma, Non-Small-Cell Lung
3
Recurrence
2
Melanoma
2
Lymphoma
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Triple Negative Breast Neoplasms
1
Solid Tumors
1
Prostatic Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Hodgkin Disease
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Craniopharyngioma
1
Interventions
tocilizumab
1
atezolizumab
1
Tiragolumab
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Advanced Liver Cancers
×
tocilizumab
×
90 days
×
Clear all
NCT04524871
2026-05-22
MORPHEUS-LIVER
Hoffmann-La Roche
Phase 1/2
Recruiting
518 enrolled